## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.47 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($89.34)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Boston Scientific Corporation $BSX Shares Purchased by State Street Corp**
- Source: MarketBeat | 20251209T131410 | Somewhat-Bullish | Relevance: 98%
-  State Street Corp increased its stake in Boston Scientific Corporation (NYSE:BSX) by 1.1% in Q2, acquiring 713,379 additional shares, bringing its total to over 65 million shares valued at approximately $7 billion. Despite institutional buying, company insiders have recently sold over 143,000 shares worth $14.23 million. Boston Scientific reported strong Q3 earnings, beating analyst estimates, and maintains a consensus "Buy" rating with an average target price of $123.77.

**2. Boston Scientifc pays $188 million for newly built Maple Grove facility**
- Source: The Business Journals | 20251208T130806 | Bullish | Relevance: 98%
- Boston Scientific has paid $188 million for a newly constructed, 400,000-square-foot facility in Maple Grove, expanding its significant presence in the northwest metro. The company's continued growth in the area is highlighted by this substantial real estate acquisition.

**3. Boston Scientific buys major Minneapolis-area property for $188M**
- Source: NBC Boston | 20251209T120809 | Somewhat-Bullish | Relevance: 97%
-  Boston Scientific Corp. has acquired its newly opened 400,000-square-foot facility in Maple Grove, a suburb of Minneapolis, for $188.8 million. This acquisition represents one of the largest commercial real estate transactions of the year. The Maple Grove City Council had previously approved plans for the facility.

**4. Precision oncology at your communityâ€™s doorstep**
- Source: Illumina | 20251208T151032 | Somewhat-Bullish | Relevance: 59%
-  Illumina is making comprehensive genomic profiling (CGP) testing more accessible to community cancer care centers. This allows in-house labs to utilize CGP, which assesses hundreds of genes and biomarkers, to improve therapeutic options and patient outcomes. The move aims to decentralize CGP testing, reducing turnaround times and operational barriers for local oncology practices.

**5. Terns Pharmaceuticals stock hits all-time high at 29.53 USD**
- Source: Investing.com | 20251206T113200 | Somewhat-Bullish | Relevance: 58%
-  Terns Pharmaceuticals Inc. stock has reached an all-time high of 29.53 USD, demonstrating a remarkable 340.53% increase over the past year. This growth is bolstered by positive Phase 1 data for its TERN-701 treatment and subsequent price target increases from several analysts including Citizens, Truist Securities, BMO Capital, and Mizuho. The company's performance reflects strong investor confidence and promising developments in its therapeutic programs.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.0% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 7.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $139.1B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 27.1 |
| Current P/E | 30.9 |
| YoY Growth | 14.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.9% to -7.9% (-5.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.9pp (needs >4.0% for momentum thesis). AM_20 at -6.0% indicates price below own 20MA trend. Underperforming sector by 4.5pp, stock-specific weakness. Below SMA200 (0.93x), long-term trend not supportive. MACD histogram bearish (-0.54), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.90% (CS: 3) | Weak |
| RSI_14 | 33.4 | Neutral |
| MACD Histogram | -0.54 | Bearish |
| vs SMA20 | 0.940x | Below |
| vs SMA50 | 0.947x | Below |
| vs SMA200 | 0.926x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $93.84
- **Stop Loss:** $89.34 (4.8% risk)
- **Target:** $102.84 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 111
- **Position Value:** $10,416.24
- **Portfolio %:** 10.42%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*